Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma

Cochrane Database of Systematic Reviews

Volumn 2012, Issue 8, 2012, Pages

  Vale, Claire L ^a   Tierney, Jayne ^b   Bull, Sarah J ^a   Symonds, Paul R ^c  

^a MRC CLINICAL TRIALS UNIT   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c LEICESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FILGRASTIM; FLUOROURACIL; IFOSFAMIDE; MEGESTROL; MELPHALAN; PACLITAXEL; ANTINEOPLASTIC AGENT;

ACUTE TOXICITY; ADVANCED CANCER; ADVERSE EVENT; ALOPECIA; ANEMIA; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RECURRENCE; CLINICAL EFFECTIVENESS; CYTOTOXICITY; DIARRHEA; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG FATALITY; ENDOMETRIUM CARCINOMA; GASTROINTESTINAL TOXICITY; GRANULOCYTOPENIA; HUMAN; INTERVENTION STUDY; KIDNEY FAILURE; LEUKOPENIA; META ANALYSIS; METASTASIS; NAUSEA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEPSIS; SIDE EFFECT; SYSTEMATIC REVIEW; THERAPY EFFECT; THROMBOCYTOPENIA; TUMOR REGRESSION; UTERUS SARCOMA; VOMITING; ENDOMETRIUM TUMOR; FEMALE; PATHOLOGY; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84866769698     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD003915.pub4     Document Type: Review

References (40)

1. Aapro M, Bolis G, Chevallier B, van der Burg MEL, Poveda A, de Oliveira C, et al.An EORTC-GCCG randomized phase II trial of doxorubicin versus dox-cisplatin (cDDP) in endometrial carcinoma. Proceedings of the Annual Meeting of the American Society of Clinical Oncology. 1994; Vol. 13, issue Abstract 885:275.
2. Aapro MS, van Wijk FH, Bolis G, Chevallier B, van der Burg MEL, Poveda A, et al on behalf of the EORTC-GCCG. Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC-GCCG. Annals of Oncology 2003;14:441-8.
3. Cohen CJ, Bruckner HW, Deppe G, Blessing JA, Homesley H, Lee JH, et al.Multidrug treatment of advanced and recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Obstetrics and Gynecology 1984;63(5):719-26.
4. Edmonson JH, Krook JE, Hilton JF, Malkasian GD, Everson LK, Jefferies JA, et al.Randomized phase II studies of cisplatin and a combination of cyclophosphamide-doxorubicin-cisplatin (CAP) in patients with progestin-refractory advanced endometrial carcinoma. Gynecologic Oncology 1987;28(1):20-4.
5. Fleming GF, Brunetto VL, Cella D, Look KY, Reid GC, Munkarah AR, et al.Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. Journal of Clinical Oncology 2004;22(11):2159-66.
6. Fleming GF, Brunetto VL, Mundt AJ, Burks RT, Look KY, Reid G. Randomised trial of doxorubicin (DOX) plus cisplatin (CIS) versus DOX plus CIS plus paclitaxel (TAX) in patients with advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group (GOG) study. Proceedings of American Society of Clinical Oncology. 2002; Vol. 21:202a Abstract 807.
7. Fleming GF, Filiaci VL, Bentley RC, Herzog T, Vaccarello L, Gallion H. Phase III randomised trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study. Annals of Oncology 2004;15:1173-8.
8. Gallion HH, Brunetto VL, Cibull M, Lentz SS, Reid G, Soper JT, et al.Randomized phase III trial of standard timed doxorubicin plus cisplatin versus circadian timed doxorubicin plus cisplatin in stage III and IV or recurrence endometrial carcinoma: a Gynecologic Oncology Group study. Journal of Clinical Oncology 2003;21(20):3808-13.
9. Horton J, Begg CB, Arseneault J, Bruckner H, Creech R, Hahn RG. Comparison of adriamycin with cyclophosphamide in patients with advanced endometrial cancer. Cancer Treatment Reports 1978;62(1):159-61.
10. Horton J, Elson P, Gordon P, Hahn R, Creech R. Combination chemotherapy for advanced endometrial cancer. An evaluation of three regimens. Cancer 1982;49:2241-5.
11. Long HJ, Nelimark RA, Cha SS. Comparison of methotrexate, vinblastine, doxorubicin and cisplatin (MVAC) vs doxorubicin and cisplatin (AC) in advanced endometrial carcinoma. Proceedings of the Annual Meeting of the American Society of Clinical Oncology. 1995; Vol. 14:282 Abstract 797.
12. Long III H, Nelimark R, Podratz K, Suman V, Keeney G, Nikcevich D, et al.Phase III comparison of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) vs. doxorubicin and cisplatin (AC) in women with advanced primary or recurrent metastatic carcinoma of the uterine endometrium. Gynecologic Oncology 2006;100:501-5.
13. Nomura H, Aoki D, Takahashi F, Katsumata N, Watanabe Y, Konishi I, et al.Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: Japanese Gynecologic Oncology Group trial (JGOG2041). Journal of Clinical Oncology (ASCO Meeting Abstracts). 2008; Vol. 26:16526.
14. Nomura H, Aoki D, Takahashi F, Katsumata N, Watanabe Y, Konishi I, et al.Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: a Japanese Gynecologic Oncology Group study (JGOG2041). Annals of Oncology 2011;22(3):636-42.
15. Nomura H, Aoki D, Takahashi F, Katsumata N, Watanabe Y, Konishi I, et al.Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: Japanese Gynecologic Oncology Group trial (JGOG2041). Journal of Clinical Oncology (ASCO Meeting Abstracts). 2008; Vol. 26:16526.
16. Nomura H, Aoki D, Takahashi F, Katsumata N, Watanabe Y, Konishi I, et al.Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: a Japanese Gynecologic Oncology Group study (JGOG2041). Annals of Oncology 2011;22(3):636-42.
17. Pawinski A, Tumolo S, Hoesel G, Cervantes A, van Oosterom AT, Hoctin Boes G, et al.Cyclophosphamide or ifosfamide in patients with advanced and/or recurrent endometrial carcinoma: a randomised phase II study of the EORTC Gynecological Cancer Cooperative Group. European Journal of Obstetrics and Gynecology and Reproductive Biology 1999;86:179-83.
18. Thigpen J, Blessing P, DiSaia P, Ehrlich C for the Gynecologic Oncology Group. A randomized comparison of adriamycin with or without cyclophosphamide in the treatment of advanced or recurrent endometrial carcinoma. Proceedings of the American Society of Clinical Oncology. 1985:115 Abstract C-448.
19. Thigpen JT, Blessing JA, DiSaia PJ, Yordan E, Carson LF, Evers C. A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Journal of Clinical Oncology 1994;12(7):1408-14.
20. Thigpen JT, Brady MF, Homesley, Malfetano J, DuBeshter B, Burger RA, et al.Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a Gynecologic Oncology Group Study (GOG). Journal of Clinical Oncology 2004;22(19):3902-8.
21. Thigpen T, Blessing J, Homesley H, Malfetano J, DiSaia P, Yordan E. Phase III trial of doxorubicin ± cisplatin in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group (GOG) study. Proceedings of the American Society of Clinical Oncology. 1993; Vol. 12:261 Abstract 830.
22. Weber B, Mayer F, Bougnoux P, Lesimple T, Joly F, Fabbro M, et al.What is the best chemotherapy regimen in recurrent or advanced endometrial carcinoma? Preliminary results. Proceedings of the American Society of Clinical Oncology. 2003; Vol. 22:Abstract 1819.
23. Reed NS (Investigator). Doxorubicin and cisplatin with or without paclitaxel in treating patients with locally advanced, metastatic and/or relapsed endometrial cancer. http://clinicaltrials.gov/ct2/show/record/NCT00052312.
24. Miller D (Protocol chair). Randomized phase III trial of doxorubicin/cisplatin/paclitaxel and G-CSF versus carboplatin/paclitaxel in patients with stage III and IV or recurrent endometrial cancer. http://clinicaltrials.gov/ct/show/NCT0006399.
25. Bremond A, Bataillard A, Thomas L, Achard JL, Fervers B, Fondrinier E, et al.Cancer of the endometrium. British Journal of Cancer 2001;84(supple 2):31-6.
26. Burke TW, Heller PB, Woodward J, Davidson SA, Hoskins WJ, Park RC, et al.Treatment failure in endometrial carcinoma. Obstetrics and Gynaecology 1990;75:96-101.
27. Cullen MH, Woodroffe CM, Billingham LJ, Chetiyarwardana AD, Joshi R, Ferry D, et al.Mitomycin, ifosfamide and cisplatin (MIC) in unresectable non-small cell lung cancer: effects on survival and quality of life. Journal of Clinical Oncology 1999;17(10):3188-94.
28. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. The Lancet 1998;351:1451-67.
29. Faust G, Davies Q, Symonds P. Changes in the treatment of endometrial cancer. British Journal of Obstetrics and Gynaecology 2010;117:1043-6.
30. Creasman W. Revised FIGO staging for carcinoma of the endometrium. International Journal of Gynaecology and Obstetrics 2009;105(2):109.
31. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global Cancer Statistics. CA: Cancer Journal for Clinicians 2011;61:69-90.
32. Johnson N, Bryant A, Miles T, Hogberg T, Cornes P. Adjuvant chemotherapy for endometrial cancer after hysterectomy. Cochrane Database of Systematic Reviews 2011, Issue 10. [DOI: 10.1002/14651858.CD003175.pub2].
33. Kokka F, Brockbank E, Oram D, Gallagher C, Bryant A. Hormonal therapy in advanced or recurrent endometrial cancer. Cochrane Database of Systematic Reviews 2010, Issue 12. [DOI: 10.1002/14651858.CD007926.pub2].
34. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
35. Morris M, Alvarez RD, Kinney WK, Wilson TO. Treatment of recurrent adenocarcinoma of the endometrium with pelvic exenteration. Gynecologic Oncology 1996;60:288.
36. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17:2815-34.
37. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16.
38. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Progress in Cardiovascular Diseases 1985;27(5):335-71.
39. Humber CE, Tierney J, Symonds PR, Collingwood M, Kirwan JJ, Williams C, et al.Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma. Cochrane Database of Systematic Reviews 2005, Issue 4. [DOI: 10.1002/14651858.CD003175.pub2].
40. Humber CE, Tierney JF, Symonds RP, Collingwood M, Kirwan J, Williams C, et al.Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration. Annals of Oncology 2007;18(3):409-20.